What is it?
DirectLenderMatch classifies Royalty-Backed Loan under the financing form “Secured cash-flow loan.” Its typical use in this directory is: Borrow against future royalties.
How does it work?
The structure is generally evaluated, supported, or secured using the following basis: Contractual royalty stream. Exact underwriting, eligibility, terms, and availability are provider-specific and can change.
What can it be used for?
Borrow against future royalties.
What backs or supports it?
Contractual royalty stream.
Why does this structure exist?
This structure provides a defined way to address the financing need described above. The provider, transaction, collateral, and underwriting context determine how the structure is implemented in practice.
Important considerations
Confirm current costs, risks, licensing, eligibility, collateral treatment, recourse, tax consequences, and availability directly with the provider and appropriate professional advisers. DirectLenderMatch does not compare rates or recommend products.
Is this actually a loan?
Workbook classification: Yes. Financing forms such as leases, purchases, shared equity, advances, and guarantees may solve a funding need without being conventional loans.
Verified lenders or providers
Direct royalty-finance provider
Royalty Pharma
Royalty Pharma provided a $250 million nonrecourse royalty-backed note financing in March 2026.
Official evidence page →Last verified: 2026-08-23
Direct bank lender
East West Bank
East West Bank includes royalty monetization among its structured-finance capabilities.
Official evidence page →Last verified: 2026-08-24
Related financing structures
Pharmaceutical Royalty Financing
Monetize or borrow against pharmaceutical royalties
Music Royalty Monetization
Receive lump sum against catalog/royalty income
Intellectual-Property-Backed Loan
Borrow against IP value/cash flow
Legal-Fee Receivables Financing
Advance/borrow against billed legal fees
Licensing-Receivables Financing
Borrow against licensing income
Patent-Backed Loan
Borrow against patent value/licensing economics